News by Subject
News by Disease
News by Date
Post Your News
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
US & Canada
Post an Event
News | News By Subject | News by Disease |
News By Date | Search News
Coriolis Pharma Release: 2013 Munich Protein Formulation And Stability Conference
11/18/2013 11:11:53 AM
Munich/Martinsried (Germany), November 18, 2013. Coriolis Pharma
(www.coriolis-pharma.com), a globally operating biopharmaceutical research
and development service provider, organized a top-class scientific conference
in Munich, Germany to mark its fifth anniversary. Around 130 participants had
the opportunity to find out more about the latest scientific findings in
formulation development and the stability of protein therapeutics. Prof. John
Carpenter (University of Colorado) joined renowned international experts such
as Prof. Wim Jiskoot (Leiden Academic Center for Drug Research), Prof.
Gerhard Winter (Ludwig-Maximilian University, Munich), Prof. Wolfgang Friess
(Ludwig-Maximilian University, Munich) and Prof. Christian Schoeneich
(University of Kansas) at the conference.
As one of the keynote speakers at the 2013 Munich Protein Formulation and
Stability Conference, Prof. John Carpenter explained to participants from the
fields of science and industry how various biopharmaceutical manufacturing
methods can influence the development of protein particles and how these
processes can be monitored.
Protein Particles Cause Immunogenicity
Many suspect that such particle formation is one of the causes of
immunogenicity reactions in patients following administration of
biopharmaceuticals. Prof. Christian Schoeneich and Prof. Wim Jiskoot also
took a look at this issue in their presentations. The renowned protein
researchers all agreed that there is mounting evidence indicating that
undesired protein particles can provoke immune responses in patients. Prof.
Gerhard Winter gave participants insights into current trends in the freezedrying
of biologics. His colleague Prof. Wolfgang Friess, also from the
University of Munich’s Department of Pharmacy, Pharmaceutical Technology
and Biopharmaceutics, spoke about the aggregation of monoclonal antibodies.
Dr. Andrea Hawe, Chief Scientific Officer of Coriolis Pharma, rounded out the
program with an overview of established and emerging techniques for
aggregate and particle characterization in biopharmaceuticals.
The service provider Coriolis Pharma organized the one-day conference on
October 17 to mark its fifth anniversary. A specialized provider with high
scientific standards, the independent privately owned company supports the
biopharmaceutical industry in research and development projects in the fields
of protein analysis and formulation development for biotechnological drugs.
Background: Coriolis Pharma
Coriolis Pharma is a globally operating independent service provider for
formulation research and contract analysis of biopharmaceutical drugs
(proteins, peptides, monoclonal antibodies and vaccines). Coriois Pharma
provides formulation development and testing, pre-clinical material
manufacturing, lyophilization processes, stability testing and innovative
analytical services on behalf of pharmaceutical companies. The company is
based in the German town of Martinsried, near Munich (www.coriolispharma.
Help employers find you! Check out all the jobs and post your resume.